Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Demodex mites are microscopic arthropods that inhabit the hair follicles and sebaceous glands of the human skin, particularly at the eyelid margin. The two main species affecting humans are Demodex folliculorum and Demodex brevis. These organisms are part of the normal skin microbiome in most adults but can become pathogenic when they overpopulate or when host immunity is compromised[3][4][5]. At high densities on the lid margin, they contribute to chronic blepharitis—a persistent inflammation characterized by symptoms such as itching (especially at night), redness, burning sensation, tearing, foreign body sensation in the eye, trichiasis (misdirected lashes), madarosis (lash loss), and cylindrical dandruff or "collarettes" around lash bases[1][2][4][5]. Demodex infestation causes disease through several mechanisms: - Mechanical damage from their claws leads to microabrasions and inflammation. - Their feeding activity destroys epithelial cells. - They act as vectors for bacteria like Staphylococci and Streptococci; these bacteria may further exacerbate inflammation by producing superantigens[1][7]. - Waste products from digestion accumulate as collarettes around lashes. The presence of cylindrical collarettes is considered pathognomonic for Demodex blepharitis—these waxy sleeves consist mainly of undigested material mixed with epithelial debris and mite eggs[2]. Diagnosis is often clinical but can be confirmed by microscopic examination. While not a molecular target such as a receptor or enzyme—and thus not a therapeutic target in the conventional sense—treatments aim to reduce mite load using topical acaricides like tea tree oil derivatives. Proper lid hygiene is also essential for management. There are no specific molecular biomarkers beyond clinical signs such as collarettes. This entry is considered incorrect as a "target" because "Bacteria/Demodex at lid margin" refers collectively to both microbial flora and parasitic infestation rather than a single molecule or receptor amenable to direct pharmacological targeting. Instead, it describes an ecological niche involving multiple organisms contributing to disease pathology rather than one canonical druggable entity[1][2][3].
Eradication or reduction of mite population via acaricidal agents (e.g., tea tree oil disrupts cell membranes of mites)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Demodex mite at eyelid margin (null).